Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 15% Improvement Relative Risk ICU admission -2% Recovery -10% Favipiravir  Khamis et al.  LATE TREATMENT  RCT Is late treatment with favipiravir + interferon beta-1b beneficial for COVID-19? RCT 89 patients in Oman (June - August 2020) Trial compares with HCQ, results vs. placebo may differ Trial underpowered for serious outcomes c19early.org Khamis et al., Int. J. Infectious Dise.., Nov 2020 Favors favipiravir Favors HCQ

Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia

Khamis et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.008
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Small 89 patient RCT comparing favipiravir and inhaled interferon with HCQ for moderate to severe COVID-19 pneumonia, not finding significant differences. There was no control group.
This study is excluded in the after exclusion results of meta analysis: study compares against another treatment showing significant efficacy.
Study covers HCQ and favipiravir.
risk of death, 14.8% lower, RR 0.85, p = 1.00, treatment 5 of 44 (11.4%), control 6 of 45 (13.3%), NNT 51, day 14.
risk of ICU admission, 2.3% higher, RR 1.02, p = 1.00, treatment 8 of 44 (18.2%), control 8 of 45 (17.8%).
risk of no recovery, 9.6% higher, RR 1.10, p = 0.82, treatment 15 of 44 (34.1%), control 14 of 45 (31.1%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Khamis et al., 9 Nov 2020, Randomized Controlled Trial, Oman, peer-reviewed, 11 authors, study period 22 June, 2020 - 13 August, 2020, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with interferon beta-1b) - results of individual treatments may vary.
This PaperFavipiravirAll
Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia
Faryal Khamis, Hanan Al Naabi, Adil Al Lawati, Zaiyana Ambusaidi, Mariam Al Sharji, Umkulthum Al Barwani, Nenad Pandak, Zakariya Al Balushi, Maher Al Bahrani, Issa Al Salmi, Ibrahim Al-Zakwani
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.008
To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia. Methods: A randomized, open-label controlled trial of oral favipiravir in adults hospitalized with moderate to severe COVID-19 pneumonia from June 22nd 2020 to August 13th 2020 was conducted. Patients were randomly assigned to receive either a combination of favipiravir with interferon beta-1b by inhalation aerosol or hydroxychloroquine (HCQ). The outcome endpoints included improvement in inflammatory markers, lower length of hospital stay (LOS), discharges and lower overall 14-day mortality. Results: A total of 89 patients underwent randomization with 49% (n = 44) assigned to favipiravir and 51% (n = 45) assigned HCQ. The overall mean age was 55 AE 14 years and 58% (n = 52) were males. There were no significant differences in the inflammatory biomarkers at hospital discharge between the two groups; C-reactive protein (p = 0.413), ferritin (p = 0.968), lactate dehydrogenase (p = 0.259) and interleukin 6 (p = 0.410). There were also no significant differences between the two groups with regards to the overall LOS (7 vs 7 days; p = 0.948), transfers to the ICU (18.2% vs 17.8%; p = 0.960), discharges (65.9% vs 68.9%; p = 0.764) and overall mortality (11.4% vs 13.3%; p = 0.778). Conclusions: No differences in clinical outcomes were found between favipiravir plus inhaled interferon beta-1b and hydroxychloroquine in adults hospitalized with moderate to severe COVID-19 pneumonia.
Conflicts of interest The authors have no conflicts of interest to declare.
References
Agrawal, Raju, Udwadia, Favipiravir: a new and emerging antiviral option in COVID-19, Med J Armed Forces India
Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: an Open-Label Control Study
Doi, Ikeda, Hayase, Moriya, Morimura et al., Study Group. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series, Crit Care
Dong, Hu, Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug Discov Ther
Fang, Wang, Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir, Biosafety Health
Faryal, Badria, Ibrahim, Ahmed, Salah, Epidemiology of COVID-19 infection in Oman: analysis of the first 1304 cases, Oman Med J
Freedman, Selchen, Arnold, Prat, Banwell et al., Treatment optimization in MS: Canadian MS Working Group updated recommendations, Can J Neurol Sci
Fu, Liu, Xia, Li, Song et al., A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-k plus TFF2 in patients with moderate COVID-19, E Clin Med
Furuta, Gowen, Takahashi, Shiraki, Smee et al., Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study on hydroxychloroquine in hospitalized patients with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2012410
Gonçalves, Bertrand, Ke, Commets, De Lamballerie et al., Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral, CPT Pharmacometrics Syst Pharmacol
Hung, Lung, Tso, Liu, Chung et al., Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, Lancet
Hurwitz, Jeffery, Arnason, Bigley, Coyle et al., Tolerability and safety profile of 12-to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study, Clin Ther
Kaptein, Jacobs, Langendries, Seldeslachts, Horst et al., Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity, Proct Natl Acad Sci
Khamis, Al Naabi, Lawati, None, International Journal of Infectious Diseases
Khamis, Al Naabi, Lawati, None, International Journal of Infectious Diseases
Kumari, Rawat, Saha, Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update, Curr Pharmacol Rep
Lampl, Nagl, Arnason, Comi, Connor et al., Efficacy and safety of interferon beta-1b sc in older RRMS patients-a posthoc analysis of the BEYOND study, J Neurol
Lee, Hsueh, Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV, J Microbiol Immunol Infect
Lokugamage, Hage, De Vries, Valero-Jimenez, Schindewolf et al., Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV, J Virol, doi:10.1128/JVI.01410-20
Lu, Drug treatment options for the 2019-new coronavirus (2019-nCoV), Biosci Trends
Madelain, Nguyen, Olivo, De Lamballerie, Guedj et al., Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials, Clin Pharmacokinet
Madelain, Oestereich, Graw, Nguyen, De Lamballerie et al., Ebola virus dynamics in mice treated with favipiravir, Antiviral Res
Malvy, Taburet, De Lamballerie, Mentre, Extramiana, The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers, PLoS Negl Trop Dis
Mdvi, Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults
Mentré, Taburet, Guedj, Anglaret, Keita et al., Dose regimen of favipiravir for Ebola virus disease, Lancet Infect Dis
Moriguchi, Sato, Treatment of SARS with human interferons, Lancet, doi:10.1016/S0140-6736(03)14484-4
Nguyen, Guedj, Anglaret, Laouenan, Madelain et al., Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS Negl Trop Dis
Oestereich, Lüdtke, Wurr, Rieger, Muñoz-Fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res
Pilkington, Pepperrell, Hill, A review of the safety of favipiravir -a potential treatment in the COVID-19 pandemic?, J Virus Erad
Sallard, Lescure, Yazdanpanah, Mentre, Peiffer-Smadja, Type 1 interferons as a potential treatment against COVID-19, Antiviral Res
Shalhoub, Interferon beta-1b for COVID-19, Lancet
Shiraki, Daikoku, Favipiravir, an anti-influenza drug against life-threatening RNA virus infections, Pharmacol Ther
Sissoko, Laouenan, Folkesson, Lebing, Beavogui et al., Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, PLoS Med
Smith, Dodds, Bentley, Yeo, Rayner, Dosing will be a key success factor in repurposing antivirals for COVID-19, Br J Clin Pharmacol, doi:10.1111/bcp.14314
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomised, controlled trial, BMJ, doi:10.1136/bmj.m1849
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit